复星创新药汉斯状在英国、印度、新加坡和马来西亚获批上市

中金在线2025-06-30

2025年6月，复星国际(00656.HK)生物创新药平台——复宏汉霖自主研发的抗PD-1单抗H药汉斯状获英国药品和保健品监管局、印度中央药品标准控制组织批准，用于广泛期小细胞肺癌(ES-SCLC)的一线治疗；当月汉斯状还获得新加坡卫生科学局和马来西亚国家药品监管局批准，用于治疗ES-SCLC。肺癌是全球发病率和死亡率最高的恶性肿瘤，小细胞肺癌是肺癌中侵袭性最强的亚型，约占肺癌总数的15%，据统计...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2547409883?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-30 17:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2547409883","market":"hk","top_or_hot":-1,"title":"复星创新药汉斯状在英国、印度、新加坡和马来西亚获批上市","media":"中金在线","content":"<div>\n<p>2025年6月，复星国际(00656.HK)生物创新药平台——复宏汉霖自主研发的抗PD-1单抗H药汉斯状获英国药品和保健品监管局、印度中央药品标准控制组织批准，用于广泛期小细胞肺癌(ES-SCLC)的一线治疗；当月汉斯状还获得新加坡卫生科学局和马来西亚国家药品监管局批准，用于治疗ES-SCLC。肺癌是全球发病率和死亡率最高的恶性肿瘤，小细胞肺癌是肺癌中侵袭性最强的亚型，约占肺癌总数的15%，据统计...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063018025195311d9c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星创新药汉斯状在英国、印度、新加坡和马来西亚获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星创新药汉斯状在英国、印度、新加坡和马来西亚获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-30 17:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063018025195311d9c&s=b><strong>中金在线</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年6月，复星国际(00656.HK)生物创新药平台——复宏汉霖自主研发的抗PD-1单抗H药汉斯状获英国药品和保健品监管局、印度中央药品标准控制组织批准，用于广泛期小细胞肺癌(ES-SCLC)的一线治疗；当月汉斯状还获得新加坡卫生科学局和马来西亚国家药品监管局批准，用于治疗ES-SCLC。肺癌是全球发病率和死亡率最高的恶性肿瘤，小细胞肺癌是肺癌中侵袭性最强的亚型，约占肺癌总数的15%，据统计...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063018025195311d9c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063018025195311d9c&s=b","article_id":"2547409883","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063018025195311d9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2547409883","pubTimestamp":1751275748,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年6月，复星国际生物创新药平台——复宏汉霖自主研发的抗PD-1单抗H药汉斯状获英国药品和保健品监管局、印度中央药品标准控制组织批准，用于广泛期小细胞肺癌的一线治疗；当月汉斯状还获得新加坡卫生科学局和马来西亚国家药品监管局批准，用于治疗ES-SCLC。汉斯状是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，截至目前已在全球30多个国家和地区获批上市，惠及逾11万名患者。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1574":"生物医药B类股","BK1230":"工业集团企业","06978":"永泰生物-B","02196":"复星医药","00656":"复星国际","BK1161":"生物科技"},"translate_title":"Fosun's innovative drug Hans is approved for marketing in the UK, India, Singapore and Malaysia","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9,"00656":0.9,"06978":1},"content_text":"2025年6月，复星国际(00656.HK)生物创新药平台——复宏汉霖自主研发的抗PD-1单抗H药汉斯状获英国药品和保健品监管局、印度中央药品标准控制组织批准，用于广泛期小细胞肺癌(ES-SCLC)的一线治疗；当月汉斯状还获得新加坡卫生科学局和马来西亚国家药品监管局批准，用于治疗ES-SCLC。肺癌是全球发病率和死亡率最高的恶性肿瘤，小细胞肺癌是肺癌中侵袭性最强的亚型，约占肺癌总数的15%，据统计，约80%的患者首次确诊已处于广泛期阶段，且临床病情恶化快，总体预后不良。汉斯状是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，截至目前已在全球30多个国家和地区获批上市，惠及逾11万名患者。本月，汉斯状进入主流成熟市场及越来越多的新兴市场，有望加快其在当地的覆盖进程，缓解该领域的迫切临床需求，为更多患者带来实质性的治疗获益，进一步拓展这款创新免疫治疗方案的全球可及性。目前，复宏汉霖正在美国开展一项汉斯状对比一线标准治疗阿替利珠单抗用于ES-SCLC的头对头桥接试验，以支持其美国上市申报。此外，汉斯状治疗SCLC已获美国食品和药品监督管理局(FDA)、欧盟委员会(EC)、瑞士药品监督管理局(Swissmedic)授予孤儿药资格，并获韩国食品药品安全部(MFDS)授予用于ES-SCLC孤儿药资格。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547409883","isCrawlerRequest":true}